Unlock stock picks and a broker-level newsfeed that powers Wall Street.
NasdaqCM - Delayed Quote USD

Sonoma Pharmaceuticals, Inc. (SNOA)

Compare
2.1900
-0.2200
(-9.13%)
At close: 4:00:00 PM EDT
2.2400
+0.05
+(2.28%)
After hours: 5:53:31 PM EDT
Loading Chart for SNOA
  • Previous Close 2.4100
  • Open 2.3300
  • Bid --
  • Ask --
  • Day's Range 2.1200 - 2.3950
  • 52 Week Range 1.9000 - 9.4000
  • Volume 138,760
  • Avg. Volume 1,611,357
  • Market Cap (intraday) 3.539M
  • Beta (5Y Monthly) 1.56
  • PE Ratio (TTM) --
  • EPS (TTM) -2.2600
  • Earnings Date Jun 16, 2025 - Jun 20, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 17.00

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye and nasal care, oral care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. The company offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis; and Pediacyn, an atopic dermatitis hydrogel. It also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for use in emergencies and on mucous membranes, cuts, abrasions, burns, and body surfaces; and Endocyn root canal irrigation solutions. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

sonomapharma.com

10

Full Time Employees

March 31

Fiscal Year Ends

Recent News: SNOA

View More

Performance Overview: SNOA

Trailing total returns as of 3/31/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

SNOA
18.59%
S&P 500 (^GSPC)
4.59%

1-Year Return

SNOA
35.59%
S&P 500 (^GSPC)
6.80%

3-Year Return

SNOA
97.27%
S&P 500 (^GSPC)
23.87%

5-Year Return

SNOA
97.77%
S&P 500 (^GSPC)
117.13%

Compare To: SNOA

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: SNOA

View More

Valuation Measures

Annual
As of 3/28/2025
  • Market Cap

    3.89M

  • Enterprise Value

    -1.22M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.18

  • Price/Book (mrq)

    0.80

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -26.82%

  • Return on Assets (ttm)

    -19.72%

  • Return on Equity (ttm)

    -64.83%

  • Revenue (ttm)

    13.97M

  • Net Income Avi to Common (ttm)

    -3.75M

  • Diluted EPS (ttm)

    -2.2600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.24M

  • Total Debt/Equity (mrq)

    2.44%

  • Levered Free Cash Flow (ttm)

    1.25M

Research Analysis: SNOA

View More

Company Insights: SNOA

Research Reports: SNOA

View More

People Also Watch